Tweet
Autus Asset Management LLC raised its holdings in Abbott Laboratories (NYSE:ABT) by 3.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 127,113 shares of the healthcare product maker's stock after purchasing an additional 4,015 shares during the quarter. Abbott Laboratories accounts for about 1.4% of Autus Asset Management LLC's holdings, making the stock its 24th biggest position. Autus Asset Management LLC's holdings in Abbott Laboratories were worth $7,753,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Rainier Group Investment Advisory LLC purchased a new stake in Abbott Laboratories in the 1st quarter valued at approximately $114,000. FNY Investment Advisers LLC purchased a new stake in Abbott Laboratories in the 2nd quarter valued at approximately $118,000. Private Ocean LLC boosted its holdings in Abbott Laboratories by 9,868.2% in the 1st quarter. Private Ocean LLC now owns 2,193 shares of the healthcare product maker's stock valued at $131,000 after purchasing an additional 2,171 shares in the last quarter. Certified Advisory Corp purchased a new stake in Abbott Laboratories in the 4th quarter valued at approximately $144,000. Finally, Silvant Capital Management LLC purchased a new stake in Abbott Laboratories in the 1st quarter valued at approximately $160,000. 71.80% of the stock is currently owned by institutional investors. Get Abbott Laboratories alerts:
ABT stock opened at $64.16 on Friday. Abbott Laboratories has a 12-month low of $48.58 and a 12-month high of $65.90. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.58 and a quick ratio of 1.16. The company has a market cap of $112.33 billion, a PE ratio of 25.66, a P/E/G ratio of 1.79 and a beta of 1.53.
Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, July 18th. The healthcare product maker reported $0.73 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.71 by $0.02. Abbott Laboratories had a net margin of 3.13% and a return on equity of 15.30%. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.71 billion. During the same period last year, the firm earned $0.62 EPS. The company's revenue for the quarter was up 17.0% on a year-over-year basis. analysts forecast that Abbott Laboratories will post 2.88 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, August 15th. Stockholders of record on Friday, July 13th were given a dividend of $0.28 per share. The ex-dividend date was Thursday, July 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.75%. Abbott Laboratories's payout ratio is 44.80%.
In related news, insider Sharon J. Bracken sold 615 shares of Abbott Laboratories stock in a transaction that occurred on Monday, July 30th. The stock was sold at an average price of $65.16, for a total transaction of $40,073.40. Following the completion of the transaction, the insider now directly owns 40,761 shares in the company, valued at approximately $2,655,986.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website . Also, insider Michael J. Pederson sold 1,050 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, July 24th. The stock was sold at an average price of $63.43, for a total value of $66,601.50. Following the transaction, the insider now owns 79,467 shares of the company's stock, valued at $5,040,591.81. The disclosure for this sale can be found here . Over the last quarter, insiders have sold 17,024 shares of company stock valued at $1,088,840. Insiders own 0.74% of the company's stock.
ABT has been the topic of a number of analyst reports. Zacks Investment Research lowered Abbott Laboratories from a "buy" rating to a "hold" rating in a report on Monday, July 23rd. BTIG Research reaffirmed a "hold" rating on shares of Abbott Laboratories in a report on Sunday, April 22nd. Citigroup lowered their price objective on Abbott Laboratories from $66.00 to $65.00 and set a "neutral" rating on the stock in a report on Tuesday, April 24th. Sanford C. Bernstein initiated coverage on Abbott Laboratories in a report on Wednesday, June 27th. They issued an "outperform" rating and a $73.00 price objective on the stock. Finally, Stifel Nicolaus lifted their price objective on Abbott Laboratories from $71.00 to $72.00 and gave the company a "buy" rating in a report on Thursday, July 19th. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock has an average rating of "Buy" and an average target price of $69.88.
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; MÃ©niÃ¨re's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
Further Reading: NASDAQ Stock Market Explained
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT). Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter 